Sarepta Therapeutics’ Duchenne Muscular Dystrophy Gene Therapy Gets FDA Approval
- Sarepta Therapeutics’ Duchenne Muscular Dystrophy Gene Therapy Gets FDA Approval Barron’s
- The Price of First Gene Therapy for Muscular Dystrophy: $3.2 Million The Wall Street Journal
- Cambridge-based Sarepta Therapeutics to charge $3.2M for new Duchenne muscular dystrophy treatment WCVB Boston
- Pharmalittle: FDA approves first gene therapy for Duchenne muscular dystrophy; states join FTC to stop Amgen deal STAT
- FDA approves Duchenne Muscular Dystrophy gene therapy to address ‘urgent unmet medical need’ USA TODAY
- View Full Coverage on Google News
Read More: Sarepta Therapeutics’ Duchenne Muscular Dystrophy Gene Therapy Gets FDA Approval